Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MYB antisense RNA 1 (MYB-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the MYB gene locus on chromosome 6 in humans. Unlike protein-coding genes, MYB-AS1 does not encode a protein; instead, it likely plays a regulatory role at the RNA level. Through antisense interactions, it is believed to influence the expression of the MYB proto-oncogene, which is involved in cell proliferation, differentiation, and tumorigenesis. MYB-AS1 is implicated in diseases such as cancer due to its impact on MYB regulation, but it is not itself a therapeutic target nor an enzyme, receptor, or structural protein. No drugs are known to interact with MYB-AS1 directly, though its modulation could theoretically affect diseases where MYB is a key driver. \n\nNote: Be careful not to confuse MYB-AS1 (the lncRNA) with the protein-coding MYB transcription factor, which is a well-studied proto-oncogene and transcriptional regulator.
Not a direct therapeutic target; acts by regulating the expression of the MYB gene at the RNA level, primarily by antisense-mediated mechanisms
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MYB antisense RNA 1 (MYB-AS1).